
CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. (NYSE: UNH).
Effective September 15, the agreement covers over 51 million people throughout the United States, providing the CNSide Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT).